Presence and short‐term persistence of SARS‐CoV‐2 neutralizing antibodies in COVID‐19 convalescent plasma donors

Explore this paper's citation graph

Summary

In March 2020, the Food and Drug Administration (FDA) approved use of COVID‐19 convalescent plasma (CCP) as an investigational new drug for treatment of CO VID‐19.

Type
preprint
Published
2020-09-03
Cited by
11
References
44
Access
Open access

Keywords

Titer, Virology, Antibody, Neutralizing antibody, Convalescent plasma

References

Cited by

Related papers